Annals of Oncology
@Annals_Oncology
Medical oncology journal with a specific interest on targeted agents, immune therapies, personalised medicine, molecular pathology, bioinformatics, and more.
Stay up to date with the very latest from Annals of Oncology. Register for free to receive content and issue alerts by e-mail bit.ly/2WfW9Cb or subscribe to our RSS bit.ly/2yRH9Cp
Stay ahead with the #ESMOVirtualJournalClub – July 2025! We’re diving into new studies on #NSCLC and #GEJ cancers. Register now: 🔗 ow.ly/7Gty50WsGcz
🆕review in press: Cancer of unknown primary site and TNM staging: A new paradigm for patient management doi.org/10.1016/j.anno…
🆕review in press: Clinical challenges and proposed solutions for patients with invasive lobular breast cancer @ChristineDesme2 doi.org/10.1016/j.anno…
🆕article in press: Fracture-related hospitalisations in newly diagnosed high-risk l/m hormone-sensitive #prostatecancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data @AshwinUrol doi.org/10.1016/j.anno…
🆕article in press: Re-examining post-operative chemoradiotherapy in head and neck cancer: An updated long-term combined analysis of RTOG 9501/EORTC 22931 @sueyom @allenhomd doi.org/10.1016/j.anno…
🆕article in press: Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 vs. change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer doi.org/10.1016/j.anno…
![Annals_Oncology's tweet image. 🆕article in press: Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 vs. change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
doi.org/10.1016/j.anno…](https://pbs.twimg.com/media/GwDBFquX0AAtbrx.jpg)
📣 #ESMO25: Be where the latest breakthroughs are being shared—in real time, with real impact. Last chance to register at the most advantageous fees! ⏰ Deadline: 16 July 2025 🔗 ow.ly/5PAL50WfVKu
🆕Article in press: Neoadjuvant intralesional targeted immunocytokines (Daromun) in stage III melanoma. Read it here: annalsofoncology.org/article/S0923-…
🆕 Article in press: Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer. annalsofoncology.org/article/S0923-… @FAndreMD @Elsa2Bernard @BarbaraPistill2
🆕Annals of Oncology podcast🎧: Artificial intelligence entering the pathology arena in oncology with @tompowles1 and @antoniomarraMD tinyurl.com/m8dcm7ks To read the full article see doi.org/10.1016/j.anno…
📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents now available in 1L or at resistance. #LungCancer #mNSCLC #ESMOGuidelines 🔗 ow.ly/v7nE50Wbqsf
🆕 Article in press: Efficacy and safety of biweekly single-dose actinomycin D vs multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial annalsofoncology.org/article/S0923-…
🆕 Article in press: Health-Related Quality of life of patients with metastatic melanoma treated with tumor infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial annalsofoncology.org/article/S0923-…
📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved. 🔗 ow.ly/kzQF50Wa0lf #LungCancer #mNSCLC #ESMOGuidelines
🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer annalsofoncology.org/article/S0923-… @DrMarkAwad @BRicciutiMD
🆕 article in press: Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases annalsofoncology.org/article/S0923-…
🆕 article in press: Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations annalsofoncology.org/article/S0923-…
🆕 article in press: What is required to deliver practice changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study doi.org/10.1016/j.anno…
🆕Article of the Month podcast🎧Prof. Nick Turner @ICR_London discusses whole genome sequencing-powered ctDNA sequencing for breast cancer detection with Annals of Oncology Editor-in-Chief @tompowles1 soundcloud.com/esmo-podcasts/… To read the article see: doi.org/10.1016/j.anno…
🆕article in press: Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer doi.org/10.1016/j.anno…
